SHIPPEO
23.3.2022 11:05:05 CET | Business Wire | Press release
UNILIN , a Belgian manufacturer of flooring, panels and insulation products for the home, has chosen Shippeo , a global leader and European specialist in real-time transportation visibility, to boost service and savings.
Headquartered in Belgium, UNILIN owns 15 powerful brands (including the Quickstep flooring brand) and distributes its products in over 23 countries throughout Europe. The company operates eight key loading sites, consisting of plants, warehouses and a cross dock, and makes over 100,000 deliveries per year to specialised DIY and building supplies retailers via a network of 20 carrier partners.
A lack of visibility of external transport quality, lead times and proof of delivery led UNILIN to look for a solution that would help with supply chain optimisation and the streamlining of processes, thereby improving customer service and enabling the company to stay competitive in its market.
By implementing Shippeo’s real-time transportation visibility solution to collect location data for all deliveries, UNILIN was able to proactively inform customers about potential delays. Shippeo’s advanced ability to track Less-than-Truckload (LTL) was critical, as LTL is UNILIN’s main and most complex transportation method. Shippeo’s solution has been specifically engineered to overcome tracking challenges associated with LTL by using advanced integrations with carriers’ Transportation Management Systems (TMS) and highly accurate geofencing techniques. The live location data captured, along with automatically generated proofs of delivery, is accessible to users on the Shippeo platform portal. Delivery status information provided by Shippeo will also be made available to UNILIN customers via their own customer portal.
Following the success of the first business use case for real-time transportation visibility, UNILIN is now exploring taking advantage of Shippeo’s mobile application for more granular visibility of own fleet shipments thanks to its parcel scanning capabilities.
Shippeo’s Dennis van Bodegom, Director Northern Europe, is thrilled to be working with UNILIN: “Our organisations both share a strong commitment to excellence in service, and I’m sure Shippeo’s real-time visibility and predictive capabilities will lead to an optimised and proactive supply chain, for the benefit of UNILIN as well as their customers.”
Geert van Damme, Transport & Distribution Manager at UNILIN, said: “I did some market studies and a lot of companies came up with ideas. But the only one who could convince me to do a proof of concept was Shippeo. The ability to automatically provide our customers with real-time tracking for all our LTL deliveries is a game changer. The level of data and insight we now have access to also brings much more clarity around our delivery performance.”
About Shippeo (https://www.shippeo.com
)
LinkedIn, Facebook, Twitter
Shippeo, a global leader and European specialist in real-time transportation visibility, helps major shippers and logistics service providers leverage transportation to deliver exceptional customer service and achieve operational excellence. Their Multimodal Visibility Network connects FTL, LTL, parcel, and container transport and integrates 875+ TMS, telematics and ELD systems using a unique API. The Shippeo platform provides instant access to real-time delivery tracking, automates customer processes and offers unmatched ETA accuracy thanks to a proprietary and industry-leading algorithm developed in-house. Over 100 customers, including global brands like Coca-Cola HBC, Carrefour, Schneider Electric, Total, Faurecia, Saint-Gobain and Eckes Granini, trust Shippeo to track more than 28 million shipments per year across 75 countries.
About Unilin (https://www.unilin.com
)
Unilin Group is a global reference for interior design and building. The company engineers, manufactures and markets laminate flooring, luxury vinyl tiles, sheet vinyl, engineered parquet, carpet tiles, broadloom carpet, raw and decorative panels, industrial floors, wall and roof systems and insulation boards. Unilin employs 7.500 people at 105 locations all over the globe, 30 of which are production sites. In 2020, Unilin achieved a turnover of €2.21 billion. Customers and partners know the company as Unilin, IVC or Godfrey Hirst, or through one of its brands, such as Quick-Step, Moduleo, Utherm, Pergo, Evola, Xtratherm or ClicWall. Unilin Group is proudly part of Mohawk Industries, the world's largest flooring company with a turnover of $ 10 billion and 41.600 employees.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220322005915/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom